Cupertino, United States
PyrAmes, established in 2016, is a trailblazer in the digital health landscape, aiming to revolutionize healthcare delivery through its advanced, continuous blood pressure monitoring technology. The company’s approach is encapsulated by its slogan: "Blood pressure monitoring reimagined." Its device, Boppli®, which boasts a wireless and non-invasive design for precise monitoring, has achieved both an FDA Breakthrough Device Designation and 510(k) market clearance.
Headquartered in the United States, PyrAmes is expanding its product line with the Bosimi® and Bosimi@Home™ platforms, though these are still pending FDA clearance. In April 2021, the company secured a $6.00M Series A investment, backed by prominent investors including GSR Ventures, Keytone Ventures, Catalytic Impact Foundation, and XTX Ventures. Positioned within the Healthcare, IT, Manufacturing, and Medical Devices sectors, PyrAmes is well-poised for significant growth and impact.
